A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs
Overview
- Phase
- Phase 2
- Intervention
- Anti-PD-1 monoclonal antibody
- Conditions
- Breast Cancer
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Enrollment
- 58
- Locations
- 4
- Primary Endpoint
- Pathological Complete Remission (pCR) rate
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
This is a phase II, open-labeled, multi-centered, single-arm, investigator-initiated clinical trial of camrelizumab (an anti-PD-1 antibody) in combination with apatinib (a VEGFR2 TKI) for neoadjuvant treatment of patients with triple-negative breast cancer and >10% tumor-infiltrating lymphocytes (TILs) in baseline breast tumors. We will enroll 58 subjects (Simon's two stage design). The study is designed to evaluate the efficacy and safety of camrelizumab in combination with apatinib in the neoadjuvant treatment of TNBC with a high proportion of TILs.
Detailed Description
This a phase II, open-labeled, multi-centered, single-arm, investigator-initiated clinical trial to assess the efficacy and safety of camrelizumab combination with apatinib in female patients age of 18 to 70 with TNBC, and baseline tumor-infiltrating lymphocytes \> 10%. The number of patients to be included is 58 patients (Simon's two stage design). The primary objective is to assess the pCR. All enrolled patients will be treated with camrelizumab 200mg (iv. 3mg/kg for patient whose weight is below 50kg) on day 1 of each 21-day cycle, and apatinib 250mg daily (po, d1-d21).
Investigators
Jieqiong Liu, M.D., Ph.D.
Professor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Eligibility Criteria
Inclusion Criteria
- •Patients sign the written informed consent.
- •Women aged 18-
- •Patients with histologically confirmed operable invasive breast cancer (T1cN1-2 or T2-4N0-2)［ER-negative(IHC\<1%), PR-negative(IHC\<1%), HER2-negative（IHC-/+ or IHC++ and FISH/CISH-）］.
- •Percentage of tumor-infiltrating lymphocytes \>10% in baseline breast tumor.
- •Patients with at least one measuring lesion that was conformed to RECIST v1.1 standard.
- •No previous breast cancer-related treatment, including chemotherapy, immunotherapy, endocrine therapy, radical surgery, or radiotherapy.
- •Patients can swallow pills.
- •Eastern Cooperative Oncology Group (ECOG) performance status of ≤
- •Patients with a life expectancy of at least 12 weeks.
- •The patient's blood test results prior to enrollment met the following criteria： • Hb≥90g/L; • Plt≥100\^9/L; • Serum albumin ≥3g/dL; • Neutrophils≥1.5\^9/L;
Exclusion Criteria
- •Combination of other malignancies or previous malignancies other than breast cancer within the last 5 years, except for basal cell carcinoma or flat cell carcinoma of the skin or carcinoma in situ of the uterine cervix that has been adequately controlled by treatment.
- •Those who are not suitable for immunotherapy in combination with active infection.
- •The combination of severe non-malignant disease that would affect patient compliance or put the patient at risk.
- •Concomitant with other antineoplastic therapy or are participating in other clinical trials.
- •Male breast cancer, bilateral breast cancer or inflammatory breast cancer.
- •Patients with dementia, mental abnormality or any mental illness that prevents understanding of the informed consent form.
- •Patients with history of allergic reaction or contraindication to the use of any drug component of this trial.
- •Patients with any active autoimmune disease or a history of autoimmune disease (e.g., the following, but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enterocolitis, hepatitis, pituitary inflammation, vasculitis, nephritis, hyperthyroidism, hypothyroidism; subjects with vitiligo or whose asthma has completely resolved in childhood and does not require any intervention in adulthood may be included; (Patients with asthma that requires medical intervention with bronchodilators cannot be included).
- •Have cardiac clinical symptoms or disease that are not well controlled, such as:
- •(1) NYHA class 2 or higher heart failure; (2) Unstable angina pectoris; (3) Myocardial infarction within 1 year; (4) clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention.
Arms & Interventions
Experiment
Eligible patients enrolled receive camrelizumab 200 mg, iv, d1, every 21 days (3 mg/kg if weight \<50 kg) in combination with apatinib 250 mg, po, qd for neoadjuvant treatment for 8 cycles. Patients evaluated after neoadjuvant therapy with pCR receive 9 cycles of postoperative adjuvant camrelizumab (200 mg, iv, or 3 mg/kg if weight \<50 kg, d1,q3W) + apatinib (250 mg, po, qd). Patients with non-pCR after neoadjuvant therapy receive adjuvant chemotherapy of the physician's choice (TPC).
Intervention: Anti-PD-1 monoclonal antibody
Experiment
Eligible patients enrolled receive camrelizumab 200 mg, iv, d1, every 21 days (3 mg/kg if weight \<50 kg) in combination with apatinib 250 mg, po, qd for neoadjuvant treatment for 8 cycles. Patients evaluated after neoadjuvant therapy with pCR receive 9 cycles of postoperative adjuvant camrelizumab (200 mg, iv, or 3 mg/kg if weight \<50 kg, d1,q3W) + apatinib (250 mg, po, qd). Patients with non-pCR after neoadjuvant therapy receive adjuvant chemotherapy of the physician's choice (TPC).
Intervention: VEGFR2 Tyrosine Kinase Inhibitor
Outcomes
Primary Outcomes
Pathological Complete Remission (pCR) rate
Time Frame: After neoadjuvant study treatment and surgery, up to approximately 24-26 weeks
pCR rate (ypT0/Tis ypN0) is defined as the percentage of participants without residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy by current American Joint Committee on Cancer (AJCC) staging criteria assessed by the local pathologist at the time of definitive surgery.
Secondary Outcomes
- Objective Response Rate (ORR)(After neoadjuvant study treatment and surgery, up to approximately 24-26 weeks)
- Breast Conservation Rate(Up to approximately 24-26 weeks)
- Incidence of Treatment-Emergent Adverse Events(From the first drug administration to within 90 days for the last dose)
- Frequencies of Biomarkers(Up to approximately 24-26 weeks)
- Event-Free Survival (EFS)(Up to approximately 8 years)
- Overall Survival (OS)(Up to approximately 8 years)